Can Galafold Continue to Drive Amicus' Top Line in 2026?

Key Takeaways FOLD's Galafold delivered $371.5M in the first nine months of 2025, up 12% year over year.Patent settlement with Teva blocks Galafold generics in the United States until January 2037.FOLD's Pombiliti Opfolda earned $77.5M in nine-month 2025 sales, rising 61.5% year over year.Amicus Therapeutics (FOLD) has been making meaningful progress with its lead product, Galafold (migalastat), which has been driving the majority of the company’s revenues. The drug has remained a key top-line driver for Am ...